Literature DB >> 12767984

Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.

Jason A LaBonte1, Navid Madani, Joseph Sodroski.   

Abstract

T-tropic (X4) and dualtropic (R5X4) human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins kill primary and immortalized CD4(+) CXCR4(+) T cells by mechanisms involving membrane fusion. However, because much of HIV-1 infection in vivo is mediated by M-tropic (R5) viruses whose envelope glycoproteins use CCR5 as a coreceptor, we tested a panel of R5 and R5X4 envelope glycoproteins for their ability to lyse CCR5(+) target cells. As is the case for CXCR4(+) target cells, HIV-1 envelope glycoproteins expressed by single-round HIV-1 vectors killed transduced CD4(+) CCR5(+) cells in a membrane fusion-dependent manner. Furthermore, a CD4-independent R5 HIV-1 envelope glycoprotein was able to kill CD4-negative target cells expressing CCR5, demonstrating that CD4 is not intrinsically required for the induction of death. Interestingly, high levels of CD4 expression protected cells from lysis and syncytium formation mediated by the HIV-1 envelope glycoproteins. Immunoprecipitation experiments showed that high levels of CD4 coexpression inhibited proteolytic processing of the HIV-1 envelope glycoprotein precursor gp160. This inhibition could be overcome by decreasing the CD4 binding ability of gp120. Studies were also undertaken to investigate the ability of virion-bound HIV-1 envelope glycoproteins to kill primary CD4(+) T cells. However, neither X4 nor R5X4 envelope glycoproteins on noninfectious virions caused death in primary CD4(+) T cells. These results demonstrate that the interaction of CCR5 with R5 HIV-1 envelope glycoproteins capable of inducing membrane fusion leads to cell lysis; overexpression of CD4 can inhibit cell killing by limiting envelope glycoprotein processing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767984      PMCID: PMC156190          DOI: 10.1128/jvi.77.12.6645-6659.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  119 in total

1.  Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

Authors:  J M Harouse; A Gettie; R C Tan; J Blanchard; C Cheng-Mayer
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4(+) T cells.

Authors:  C Cicala; J Arthos; A Rubbert; S Selig; K Wildt; O J Cohen; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques.

Authors:  P A Luciw; C P Mandell; S Himathongkham; J Li; T A Low; K A Schmidt; K E Shaw; C Cheng-Mayer
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

4.  Fowlpox virus encodes a novel DNA repair enzyme, CPD-photolyase, that restores infectivity of UV light-damaged virus.

Authors:  V Srinivasan; W M Schnitzlein; D N Tripathy
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques.

Authors:  S V Narayan; S Mukherjee; F Jia; Z Li; C Wang; L Foresman; C McCormick-Davis; E B Stephens; S V Joag; O Narayan
Journal:  Virology       Date:  1999-03-30       Impact factor: 3.616

6.  CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue.

Authors:  J C Grivel; L B Margolis
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

7.  Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Authors:  M Farzan; T Mirzabekov; P Kolchinsky; R Wyatt; M Cayabyab; N P Gerard; C Gerard; J Sodroski; H Choe
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

8.  Species-specific, postentry barriers to primate immunodeficiency virus infection.

Authors:  W Hofmann; D Schubert; J LaBonte; L Munson; S Gibson; J Scammell; P Ferrigno; J Sodroski
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression.

Authors:  A M de Roda Husman; R P van Rij; H Blaak; S Broersen; H Schuitemaker
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

10.  Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.

Authors:  P Kolchinsky; T Mirzabekov; M Farzan; E Kiprilov; M Cayabyab; L J Mooney; H Choe; J Sodroski
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

View more
  14 in total

1.  Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.

Authors:  Navid Madani; Amy M Hubicki; Ana Luisa Perdigoto; Martin Springer; Joseph Sodroski
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.

Authors:  Timothy J Wilkin; Heather R Ribaudo; Allan R Tenorio; Roy M Gulick
Journal:  HIV Clin Trials       Date:  2010 Nov-Dec

3.  Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.

Authors:  Syna Kuriakose Gift; Isaac J Zentner; Arne Schön; Karyn McFadden; M Umashankara; Srivats Rajagopal; Mark Contarino; Caitlin Duffy; Joel R Courter; Mei-Yun Zhang; Jonathan M Gershoni; Simon Cocklin; Dimiter S Dimitrov; Amos B Smith; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2011-03-18       Impact factor: 3.162

4.  Movements of HIV-1 genomic RNA-APOBEC3F complexes and PKR reveal cytoplasmic and nuclear PKR defenses and HIV-1 evasion strategies.

Authors:  Mariana Marin; Sheetal Golem; Susan L Kozak; David Kabat
Journal:  Virus Res       Date:  2015-11-25       Impact factor: 3.303

5.  Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope.

Authors:  Yossef Raviv; Mathias Viard; Julian W Bess; Elena Chertova; Robert Blumenthal
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Prm1 prevents contact-dependent lysis of yeast mating pairs.

Authors:  Hui Jin; Candice Carlile; Scott Nolan; Eric Grote
Journal:  Eukaryot Cell       Date:  2004-12

7.  Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions.

Authors:  Geoffrey H Holm; Dana Gabuzda
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure.

Authors:  Geoffrey H Holm; Chengsheng Zhang; Paul R Gorry; Keith Peden; Dominique Schols; Erik De Clercq; Dana Gabuzda
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  A novel approach for producing lentiviruses that are limited to a single cycle of infection.

Authors:  David T Evans; Jennifer E Bricker; Ronald C Desrosiers
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Preferential cytolysis of peripheral memory CD4+ T cells by in vitro X4-tropic human immunodeficiency virus type 1 infection before the completion of reverse transcription.

Authors:  Yan Zhou; Lin Shen; Hung-Chih Yang; Robert F Siliciano
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.